ClinicalTrials.gg
Not yet recruitingNCT07357220Updated Jan 21, 2026

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

A Phase 1/2 interventional study of VG2025 and AK112 in Colorectal Cancer With Hepatic Metastases, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 604 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
471st of 891
72 · median 80
Started
2026
with 114 others
Phase 1/2
95 of 1,136
44 open now
Primary completion
2027-02
later than 358 of 603 live
Registered
997th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 471st largest by planned enrollment of the 891 interventional ones that give a count, is one of 115 that started in 2026, is one of 95 in phase 1/2, reaches primary completion later than 358 of the 603 other live ones, and was the 997th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.

Read the detailed description

This open-label, multicenter, phase Ib/II clinical study aims to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of AK112 in combination with VG2025, in the treatment of advanced colorectal cancer with liver metastases.

03

Conditions studied

  • Colorectal Cancer With Hepatic Metastases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Age≥18 years and ≤ 75 years
  3. or cytologically confirmed unresectable colorectal cancer with liver ; adenocarcinoma type
  4. Disease progression after first- or standard therapy
  5. At least one based on v1.1
  6. status of 0 or 1
  7. Estimated ≥3 months
  8. Adequate organ function
  9. Patients with fertility are willing to use an adequate method of

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed non-adenocarcinoma or mixed-type tumors with adenocarcinoma component ≤70%
  2. Known dMMR or MSI-H
  3. Known RAS or BRAF mutations
  4. Participation in another clinical trial
  5. Systemic anticancer therapy within 4 weeks, small molecule therapy within 2 weeks, antitumor traditional Chinese medicine within 2 weeks before first dose
  6. Prior immunotherapy other than anti-PD-(L)1 agents
  7. within 28 days before or during study treatment and 90 days after last dose
  8. Active within the past 3 years
  9. Known spinal cord compression, active brain or .
  10. Significant bleeding events requiring transfusion, invasive intervention, or hospitalization within 3 months before first dose
  11. Serious infection within 28 days, or systemic anti-infective therapy within 14 days before first dose (except antiviral therapy for /C)
  12. Active herpesvirus infection with clinical manifestations
  13. Active disease
  14. Known immunodeficiency
  15. Known allergy to study drug or , or history of severe allergic reactions to other vaccines
  16. History of allogeneic organ or hematopoietic stem cell transplantation.
  17. liver disease
  18. Any other situations that are not suitable for inclusion in this study judged by investigator
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Cohort A (VG2025+AK112)

    VG2025 (Recommended Phase II Dose), Intratumoral Injection, Q4W + AK112 (20mg/kg), ivgtt, Q2W.

    Biological: VG2025 · Drug: AK112

  • Experimental
    Cohort B (AK112)

    AK112 (20mg/kg), ivgtt, Q2W

    Drug: AK112

Interventions

  • BiologicalVG2025

    Recommended Phase II Dose, Intratumoral Injection, Q4W

  • DrugAK112

    20mg/kg, ivgtt, Q2W

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing dose-limiting toxicities (DLTs)

    Number of participants who meet the criteria of dose-limiting toxicities (DLTs) in DLT observation period

    Time frame: From Day 1 to Day 28 after the first tumour vaccine was administrated in safety run-in cohorts

  2. Number of participants with adverse events (AEs) and severity

    Number of participants experiencing adverse events (AEs) and severity, graded according to CTCAE v5.0

    Time frame: From ICF up to 30 days after last study treatment

  3. Objective Response Rate (ORR)

    Proportion of participants with complete response (CR) or partial response (PR), as assessed by RECIST version 1.1

    Time frame: Time Frame: Up to 2 years

Secondary outcomes

  1. Progression free survival (PFS)

    Time from the date of enrollment until the first documentation of disease progression or death due to any cause, whichever occurs first, as assessed by RECIST version 1.1

    Time frame: Up to 2 years

  2. Disease control rate (DCR)

    Proportion of participants with complete response (CR), partial response (PR), or stable disease (SD), as assessed by RECIST version 1.1

    Time frame: Up to 2 years

  3. Duration of response (DoR)

    Time from the first documentation of objective response to the first documented disease progression as assessed by RECIST version 1.1 or death due to any cause, whichever occurs first

    Time frame: Up to 2 years

  4. Time to response (TTR)

    Time from the start of the treatment to the first objective tumor response observed for patients who achieved complete response (CR) or partial response (PR), as assessed by RECIST version 1.1

    Time frame: Up to 2 years

  5. Overall survival (OS)

    Time from the date of enrollment to death from any cause

    Time frame: Up to 2 years

  6. Observed concentrations of AK112

    Observed serum concentrations of AK112 at different time points after AK112 administration

    Time frame: Up to 2 years

  7. Number of participants with detectable anti-drug antibodies (ADAs) to AK112

    Number of participants who develop detectable anti-drug antibodies (ADAs) to AK112

    Time frame: Up to 2 years

07

Study locations

1 site
  • The First Affiliated Hospital, Zhejiang University School of Medicine,No. 79, Qingchun Road, Shangcheng District, Hangzhou City, Zhejiang Province
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 11 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Jan 21, 2026
StartEst.
Mar 2, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2028
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357220
Lead sponsor
Akeso
Collaborators
Shanghai Virogin Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Mar 2, 2026 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
+86 (0760) 8987 3999
Tingbo Liang, MD
Contact
liangtingbo@zju.edu.cn
+86-13486180288

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion